Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 11:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–11 of 11 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Armata Pharmaceuticals, Inc. Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety and Microbiology of C16G2 Varnish Administered in Multiple Doses to Dental Subjects

NCT03004365
View directory record Official record
Conditions
Dental Caries
Interventions
C16G2 Varnish, Placebo Varnish
Drug
Lead sponsor
Armata Pharmaceuticals, Inc.
Industry
Eligibility
12 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
3
States / cities
Kalispell, Montana • Bedford, Texas • Irving, Texas
Source: ClinicalTrials.gov public record
Updated Dec 29, 2022 · Synced Oct 7, 2026, 11:26 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia

NCT05184764
View directory record Official record
Conditions
Bacteremia, Staphylococcus Aureus, Staphylococcus Aureus Bacteremia, Bacteremia Staph, Bacteremia Due to Staphylococcus Aureus
Interventions
AP-SA02, Placebo
Biological · Other
Lead sponsor
Armata Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
23
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 7, 2026, 11:26 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Phase 2 Study to Evaluate the Microbiology and Safety of C16G2 Administered to Adult and Adolescent Dental Subjects

NCT02594254
View directory record Official record
Conditions
Dental Caries
Interventions
C16G2 Gel, Placebo
Drug · Other
Lead sponsor
Armata Pharmaceuticals, Inc.
Industry
Eligibility
12 Years to 75 Years
Enrollment
135 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
10
States / cities
Imperial Beach, California • Indianapolis, Indiana • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2019 · Synced Oct 7, 2026, 11:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Ascending Dose Study of the Safety of AB-SA01 When Topically Applied to Intact Skin of Healthy Adults

NCT02757755
View directory record Official record
Conditions
Healthy Volunteers
Interventions
AB-SA01 (10^8 PFU per phage), AB-SA01 (10^9 PFU per phage), Placebo (for Cohort 10^8), Placebo (for Cohort 10^9)
Biological
Lead sponsor
Armata Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 31, 2016 · Synced Oct 7, 2026, 11:26 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Study to Evaluate the Safety and Microbiology of C16G2 in Adolescent and Adult Dental Subjects

NCT02509845
View directory record Official record
Conditions
Dental Caries
Interventions
C16G2, Placebo
Drug · Other
Lead sponsor
Armata Pharmaceuticals, Inc.
Industry
Eligibility
12 Years to 75 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
5
States / cities
Indianapolis, Indiana • Kalispell, Montana • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2019 · Synced Oct 7, 2026, 11:26 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Phase 2, Safety & Microbiology Study of C16G2 in Multiple Oral Gel &/or Mouth Rinse Doses to Healthy Adults

NCT02044081
View directory record Official record
Conditions
Dental Caries
Interventions
C16G2 Rinse, Placebo, C16G2 Gel
Drug
Lead sponsor
Armata Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
2
States / cities
Kalispell, Montana • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 1, 2019 · Synced Oct 7, 2026, 11:26 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection

NCT05616221
View directory record Official record
Conditions
Non-cystic Fibrosis Bronchiectasis, Pseudomonas Aeruginosa, Lung Infection
Interventions
AP-PA02, Placebo
Biological · Other
Lead sponsor
Armata Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
23
States / cities
Mobile, Alabama • Los Angeles, California • Farmington, Connecticut + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2026 · Synced Oct 7, 2026, 11:26 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Ph 1/2 Study Evaluating Safety and Tolerability of Inhaled AP-PA02 in Subjects With Chronic Pseudomonas Aeruginosa Lung Infections and Cystic Fibrosis

NCT04596319
View directory record Official record
Conditions
Cystic Fibrosis, Pseudomonas Aeruginosa, Pseudomonas, Lung Infection, Lung Infection Pseudomonal
Interventions
AP-PA02, Placebo
Biological · Other
Lead sponsor
Armata Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
20
States / cities
Los Angeles, California • Tampa, Florida • Boise, Idaho + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2024 · Synced Oct 7, 2026, 11:26 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Microbiology, Safety and Tolerability of C16G2 Dental Strip Application

NCT03052842
View directory record Official record
Conditions
Dental Caries
Interventions
C16G2 Strip, Placebo Strip
Drug · Other
Lead sponsor
Armata Pharmaceuticals, Inc.
Industry
Eligibility
12 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
3
States / cities
Kalispell, Montana • Bedford, Texas • Irving, Texas
Source: ClinicalTrials.gov public record
Updated Dec 22, 2022 · Synced Oct 7, 2026, 11:26 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Phase 2 Study to Evaluate the Microbiology, Safety and Tolerability of C16G2 Varnish and Strip in Adolescent and Adult Subjects

NCT03196219
View directory record Official record
Conditions
Dental Caries
Interventions
C16G2, Placebo
Drug
Lead sponsor
Armata Pharmaceuticals, Inc.
Industry
Eligibility
12 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Kalispell, Montana
Source: ClinicalTrials.gov public record
Updated Dec 22, 2022 · Synced Oct 7, 2026, 11:26 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Phase 2, Open-Label Study for Safety, Microbiology and PK of Single or Multiple Oral C16G2 Gel Doses

NCT02254993
View directory record Official record
Conditions
Dental Caries
Interventions
C16G2
Drug
Lead sponsor
Armata Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
2
States / cities
Kalispell, Montana • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 1, 2019 · Synced Oct 7, 2026, 11:26 AM EDT